Abstract

DEVELOP ORAL DOSAGE FORM OF DEFERASIROX DISPERSIBLE TABLETS

Sheik Shahanaz Begum*, Suresh Kumar P., Jagannath Patro V., Sunitha CH and Vanitha S.

ABSTRACT

Objective: Deferasirox is a once daily, oral iron chelator approved for treatment of transfusional iron overload in adult and paediatric patients. In case of iron overdose or poisoning, immediate attention deferasirox is required in the systemic circulation to counter act the iron. Hence we feel that formulation of Oro-dispersible tablets of deferasirox is an ideal approach. Methods: FTIR showed that there is no interaction between drug and excipients. Mouth dissolving tablets of Deferasirox were prepared using crospovidone, croscarmellose and sodium starch glycolate as superdisintegrants by direct compression method. Dissolution of prepared Oro-dispersible tablets of Deferasirox was performed using USP type II apparatus in 6.8 pH phosphate buffer at 50 rpm with temperature being maintained at 37±0.5oC. Samples were withdrawn at 10, 15, 20, 30 and 45min time points and were analysed using UV- visible spectrophotometer at 245 nm. Results: The tablets prepared were evaluated for various parameters like weight variation, hardness, friability, in-vitro dispersion time, drug polymer interaction, drug content, water absorption ratio and wetting time and in-vitro release and were found to be within the limits. Conclusion: Formulation with crospovidone containing superdisintegrants has shown better in-vitro dissolution profile compared with other formulations. In conclusion, development of fast dissolving tablets using superdisintegrants gives rapid drug delivery and rapid onset of action.

Keywords: Oro-dispersible tablets, Superdisintegrants, Deferasirox.